Solvonis Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • SVNS

Stock Symbol

  • Investments
  • 1

Solvonis Therapeutics General Information

Description

Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.

Contact Information

Formerly Known As
Graft Polymer (UK)
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 25 Eccleston Place
  • London SW1W 9NF
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
LON
Corporate Office
  • 25 Eccleston Place
  • London SW1W 9NF
  • England, United Kingdom

Solvonis Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Solvonis Therapeutics Stock Performance

As of 13-Nov-2026, Solvonis Therapeutics’s current market cap is $9.4M with 7.9B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.4M 7.9B 34.9M

Solvonis Therapeutics Financials Summary

As of 30-Jun-2026, Solvonis Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 13,606 26,202 6,203 151
Revenue 0 0 0 730
EBITDA (3,655)
Net Income (7,455) (7,561) (2,032) (3,878)
Total Assets 8,518 10,214 4,019 3,101
Total Debt 95 101 0 43
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Solvonis Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Solvonis Therapeutics‘s full profile, request access.

Request a free trial

Solvonis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Solvonis Therapeutics Acquisitions (1)

Solvonis Therapeutics’s most recent deal was a Merger/Acquisition with Awakn Life Sciences for . The deal was made on 27-May-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Awakn Life Sciences 27-May-2025 Merger/Acquisition Biotechnology
To view Solvonis Therapeutics’s complete acquisitions history, request access »

Solvonis Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Machinery

Industry

Rank

Percentile

Industrial Machinery

Subindustry

Rank

Percentile

To view Solvonis Therapeutics’s complete esg history, request access »

Solvonis Therapeutics FAQs

  • When was Solvonis Therapeutics founded?

    Solvonis Therapeutics was founded in 2017.

  • Where is Solvonis Therapeutics headquartered?

    Solvonis Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Solvonis Therapeutics?

    Solvonis Therapeutics has 6 total employees.

  • What industry is Solvonis Therapeutics in?

    Solvonis Therapeutics’s primary industry is Drug Discovery.

  • Is Solvonis Therapeutics a private or public company?

    Solvonis Therapeutics is a Public company.

  • What is Solvonis Therapeutics’s stock symbol?

    The ticker symbol for Solvonis Therapeutics is SVNS.

  • What is the current market cap of Solvonis Therapeutics?

    The current market capitalization of Solvonis Therapeutics is $9.4M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process